My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 10 610 / DOI: 10.3332/ecancer.2016.610

Clinical Study

Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent

Diclofenac (DCF) is a well-known and widely used non-steroidal anti-inflammatory drug (NSAID), with a range of actions which are of interest in an oncological context. While there has long been an interest in the use of NSAIDs in chemoprevention, there is now emerging evidence that such drugs may have activity in a treatment setting. DCF, which is a potent inhibitor of COX-2 and prostaglandin E2 synthesis, displays a range of effects on the immune system, the angiogenic cascade, chemo- and radio-sensitivity and tumour metabolism. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. Based on this evidence the case is made for further clinical investigation of the anticancer effects of DCF, particularly in combination with other agents - with a range of possible multi-drug and multi-modality combinations outlined in the supplementary materials accompanying the main paper.

Keywords: Drug repurposing, diclofenac, NSAID, perioperative intervention, ReDO project

Loading Article Metrics ... Please wait

Related articles

Conference Report: Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27–28 May, 2016, Rosario, Argentina

Abstract | Full Article | PDF | Spanish Published: 06 Sep 2016 / DOI: 10.3332/ecancer.2016.672

Conference Report: Highlights from the 2016 WIN Symposium, 27–29 June 2016, Paris: personalised therapy beyond next-generation sequencing

Abstract | Full Article | PDF Published: 24 Aug 2016 / DOI: 10.3332/ecancer.2016.669

Conference Report: Children’s palliative care now! Highlights from the second ICPCN conference on children’s palliative care, 18–21 May 2016, Buenos Aires, Argentina

Abstract | Full Article | PDF | Spanish Published: 23 Aug 2016 / DOI: 10.3332/ecancer.2016.667

Research: Time-dependent image changes after ethanol injection into the pancreas: an experimental study using a porcine model

Abstract | Full Article | PDF Published: 15 Aug 2016 / DOI: 10.3332/ecancer.2016.663

Review: Role of nanotechnology and gene delivery systems in TRAIL based therapies

Abstract | Full Article | PDF Published: 01 Aug 2016 / DOI: 10.3332/ecancer.2016.660



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence